tert-butyl 4-fluoroindoline-1-carboxylate | 1037075-45-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: tert-butyl 4-fluoroindoline-1-carboxylate
• 英文别名: 1,1-dimethylethyl 4-fluoro-2,3-dihydro-1H-indole-1-carboxylate；tert-butyl 4-fluoro-2,3-dihydroindole-1-carboxylate
• CAS: 1037075-45-8
• 化学式: C₁₃H₁₆FNO₂
• 分子量: 237.274
• InChiKey: NULCZUKOWGCGKE-UHFFFAOYSA-N

物化性质

• 熔点：
  45-47 °C
• 沸点：
  314.2±41.0 °C(Predicted)
• 密度：
  1.180±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-fluoroindoline-1-carboxylate 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 以76%的产率得到tert-butyl 5-bromo-4-fluoroindoline-1-carboxylate
  参考文献：
  名称：

  [EN] PERK INHIBITING INDOLINYL COMPOUNDS
  [FR] COMPOSÉS INDOLINYLE INHIBITEURS DE PERK

  摘要：

  本文提供了化合物的公式(I)、组合物和方法，用于抑制PERK并治疗相关疾病和疾病，其中Q从(Ia)、(Ib)或(Ic)中选择。

  公开号：

  WO2021041976A1
• 作为产物：
  描述：

  4-氟吲哚 在 lanthanum(III) nitrate hexahydrate 、 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 neat (no solvent) 为溶剂， 反应 2.5h， 生成 tert-butyl 4-fluoroindoline-1-carboxylate
  参考文献：
  名称：

  meta‐C−H Arylation of Aniline Derivatives via Palladium/ S,O‐Ligand/Norbornene Cooperative Catalysis

  摘要：

  摘要 芳香胺是有机分子中无处不在的分子，由于芳香胺在医药和有机电子产品中的广泛应用，其直接官能化在许多研究领域都引起了极大的兴趣。虽然有多种合成工具可以实现苯胺的正官能化和对官能化，但目前的方法却难以实现反应性较低的元位的官能化。迄今为止，苯胺衍生物的元-C-H 芳基化仅限于使用定向基团和模板，或将其转化为苯胺类和季胺盐。在此，我们首次报道了通过钯-S,O-配体-降冰片烯体系的协同催化，对非定向苯胺衍生物进行通用而高效的元-C-H-芳基化反应。该反应在温和的条件下进行，适用于多种苯胺衍生物和芳基碘化物，同时操作简单、规模可控。我们的初步机理研究--包括分离几种钯配合物和氘实验--揭示了在元-C-H 活化步骤中苯胺底物和降冰片烯介质的取代效应。

  DOI：

  10.1002/anie.202317741

文献信息

• Synthesis of Indolines via a Domino Cu-Catalyzed Amidation/Cyclization Reaction
  作者：Ana Minatti、Stephen L. Buchwald

  DOI：10.1021/ol8008792

  日期：2008.7.3

  A highly efficient one-pot procedure for the synthesis of indolines and their homologues based on a domino Cu-catalyzed amidation/nucleophilic substitution reaction has been developed. Substituted 2-iodophenethyl mesylates and related compounds afforded the corresponding products in excellent yields. No erosion of optical purity was observed when transforming enantiomerically pure mesylates under the

  已经开发了一种基于多米诺铜催化的酰胺化/亲核取代反应合成二氢吲哚及其同系物的高效一锅法。取代的 2-碘苯乙基甲磺酸酯和相关化合物以优异的产率提供了相应的产品。在反应条件下转化对映体纯的甲磺酸盐时，没有观察到光学纯度的降低。
• [EN] PERK INHIBITING INDOLINYL COMPOUNDS<br/>[FR] COMPOSÉS INDOLINYLE INHIBITEURS DE PERK
  申请人：HIBERCELL INC

  公开号：WO2021041976A1

  公开（公告）日：2021-03-04

  Provided herein are compounds of formula (I), compositions, and methods useful for inhibiting PERK and for treating related conditions diseases, and disorders, wherein Q is selected from (Ia), (Ib) ou (Ic).

  本文提供了化合物的公式(I)、组合物和方法，用于抑制PERK并治疗相关疾病和疾病，其中Q从(Ia)、(Ib)或(Ic)中选择。
• CHEMICAL COMPOUNDS
  申请人：Axten Jeffrey Michael

  公开号：US20120077828A1

  公开（公告）日：2012-03-29

  The invention is directed to substituted indoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R 1 , R 2 , and R 3 are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, ocular diseases, and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, Type 1 diabetes Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis, and arrhythmias, and more specifically cancers of the breast, colon, pancreatic, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代的吲哚啉衍生物。具体而言，本发明涉及按式I所示的化合物：其中R1、R2和R3在此定义。本发明的化合物是PERK的抑制剂，可用于治疗癌症、眼部疾病和与激活的未折叠蛋白质应答途径相关的疾病，如阿尔茨海默病、中风、1型糖尿病帕金森病、亨廷顿病、肌萎缩性侧索硬化、心肌梗死、心血管疾病、动脉硬化和心律失常，更具体地，乳腺癌、结肠癌、胰腺癌和肺癌。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还涉及使用本发明化合物或包含本发明化合物的药物组合物抑制PERK活性和治疗相关疾病的方法。
• Chemical compounds
  申请人：Axten Jeffrey Michael

  公开号：US08598156B2

  公开（公告）日：2013-12-03

  The invention is directed to substituted indoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, and R3 are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, ocular diseases, and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, Type 1 diabetes Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis, and arrhythmias, and more specifically cancers of the breast, colon, pancreatic, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代的吲哚啉衍生物。具体而言，本发明涉及符合公式I的化合物：其中R1，R2和R3在此定义。本发明的化合物是PERK的抑制剂，可用于治疗癌症、眼部疾病以及与激活的未折叠蛋白质反应途径相关的疾病，例如阿尔茨海默病、中风、1型糖尿病、帕金森病、亨廷顿病、肌萎缩侧索硬化、心肌梗死、心血管疾病、动脉粥样硬化和心律失常，更具体地是乳腺癌、结肠癌、胰腺癌和肺癌。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制PERK活性和治疗与其相关的疾病的方法。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：Constellation Pharmaceuticals, Inc.

  公开号：US20160158207A1

  公开（公告）日：2016-06-09

  The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R 1 -R 4 of formula (I) and R 1 -R 3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

  本发明涉及公式（I）或公式（II）的化合物及其盐，其中公式（I）的R1-R4和公式（II）的R1-R3具有以下定义的任何值，以及其组合物和用途。这些化合物可用作CBP和/或EP300的抑制剂。还包括含有公式（I）或公式（II）的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和盐治疗各种CBP和/或EP300介导的疾病的方法。